The Journal of Pain
Volume 8, Issue 1 , Pages 51-58 , January 2007

Reduced Presynaptic Dopamine Activity in Fibromyalgia Syndrome Demonstrated With Positron Emission Tomography: A Pilot Study

  • Patrick B. Wood

      Affiliations

    • Departments of Family Medicine and Anesthesiology, Louisiana State University Health Sciences Center–Shreveport, Shreveport, Louisiana.
    • Department of Psychiatry, Louisiana State University Health Sciences Center–Shreveport, Shreveport, Louisiana.
    • Corresponding Author InformationAddress reprint requests to Patrick B. Wood, MD, Department of Family Medicine, LSU Health Sciences Center – Shreveport, 1501 Kings Highway, Shreveport, LA 71103.
    • ,
  • James C. Patterson II

      Affiliations

    • Department of Psychiatry, Louisiana State University Health Sciences Center–Shreveport, Shreveport, Louisiana.
    • PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana.
    • ,
  • John J. Sunderland

      Affiliations

    • PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana.
    • ,
  • Kerrie H. Tainter

      Affiliations

    • PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana.
    • ,
  • Michael F. Glabus

      Affiliations

    • PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana.
    • ,
  • David L. Lilien

      Affiliations

    • PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana.

Received 13 January 2006 ,Revised 21 May 2006 ,Accepted 26 May 2006.

References 

  1. Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci. 1999;65:2269–2287
  2. Beauregard M, Ferron A, Descarries L. Comparative analysis of the effects of iontophoretically applied dopamine in different regions of the rat brain, with special reference to the cingulate cortex. Synapse. 1991;9:27–34
  3. Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM toolbox (abstract). NeuroImage. 2002;16:497
  4. Bruck A, Aalto S, Nurmi E, Bergman J, Rinne JO. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson’s disease. Neurobiol Aging. 2005;26:891–898
  5. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol. 1991;18:728–733
  6. Burkey AR, Carstens E, Jasmin L. Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci. 1999;19:4169–4179
  7. Calejesan AA, Kim SJ, Zhuo M. Descending facilitatory modulation of a behavioral nociceptive response by stimulation in the adult rat anterior cingulate cortex. Eur J Pain. 2000;4:83–96
  8. Castro NG, de Mello MC, de Mello FG, Aracava Y. Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393. Br J Pharmacol. 1999;126:1847–1855
  9. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364–378
  10. Dagher A. Functional imaging in Parkinson’s disease. Semin Neurol. 2001;21:23–32
  11. Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C, et al. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab. 1999;19:278–287
  12. Ellis KA, Nathan PJ. The pharmacology of human working memory. Int J Neuropsychopharmacol. 2001;4:299–313
  13. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults: A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci. 1998;18:5901–5907
  14. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem. 1987;48:1077–1082
  15. Ford B. Pain in Parkinson’s disease. Clin Neurosci. 1998;5:63–72
  16. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RSJ. Spatial registration and normalization of images. Hum Brain Mapp. 1995;2:165–189
  17. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp. 1995;2:189–210
  18. Gjedde A, Reith J, Dyve S, Léger G, Guttman M, Diksic M, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA. 1991;88:2721–2725
  19. Glass JM, Park DC, Minear M, Crofford LJ. Memory beliefs and function in fibromyalgia patients. J Psychosom Res. 2005;58:263–269
  20. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson’s disease. Mov Disord. 1986;1:45–49
  21. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333–1343
  22. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85:483–491
  23. Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinin H, Taiminen T, et al. Altered dopamine D2 receptor binding in atypical facial pain. Pain. 2003;106:43–48
  24. Holman AJ, Meyers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52:2495–2505
  25. Hudson JI, Goldenberg DL, Pope HG, Keck PE, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1992;92:363–367
  26. Jaaskelainen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, et al. Role of the dopaminergic system in chronic pain: A fluorodopa-PET study. Pain. 2001;90:257–260
  27. Jain AK, Carruthers BM, van de Sande MI, Barron SR, Donaldson CCS, Dunne JV, et al. Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic and treatment protocols—A consensus document. J Musculoskeletal Pain. 2004;11:3–107
  28. Jost WH. Autonomic dysfunctions in idiopathic Parkinson’s disease. J Neurol. 2003;250(Suppl 1):28–30
  29. Jost WH, Eckardt VF. Constipation in idiopathic Parkinson’s disease. Scand J Gastroenterol. 2003;38:681–686
  30. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors: Implications for models of schizophrenia. Mol Psychiatry. 2002;7:837–844
  31. Kirley A, Hawi Z, Daly G, McCarron M, Mullins C, Millar N, et al. Dopaminergic system genes in ADHD: Toward a biological hypothesis. Neuropsychopharmacology. 2002;27:607–619
  32. Kirouac GJ, Ciriello J. Cardiovascular depressor responses to stimulation of substantia nigra and ventral tegmental area. Am J Physiol. 1997;273:H2549–H2557
  33. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH, et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron. 2002;35:1111–1122
  34. Larsen JP. Sleep disorders in Parkinson’s disease. Adv Neurol. 2003;91:329–334
  35. Lauterbach EC. The neuropsychiatry of Parkinson’s disease and related disorders. Psychiatr Clin North Am. 2004;27:801–825
  36. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford). 2001;40:290–296
  37. Lopez-Avila A, Coffeen U, Ortega-Legaspi JM, del Angel R, Pellicer F. Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulate cortex. Pain. 2004;111:136–143
  38. Maldjian JA, Laurienti PJ, Burdette JB, Kraft RA. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage. 2003;19:1233–1241
  39. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: A neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord. 2003;75:77–82
  40. McKenna JE, Melzack R. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp Neurol. 2001;172:92–99
  41. Moore H, Rose HJ, Grace AA. Chronic cold stress reduces the spontaneous activity of ventral tegmental dopamine neurons. Neuropsychopharmacology. 2001;24:410–419
  42. Morgan MJ, Franklin KB. 6-Hydroxydopamine lesions of the ventral tegmentum abolish D-amphetamine and morphine analgesia in the formalin test but not in the tail flick test. Brain Res. 1990;519:144–149
  43. Nagano-Saito A, Kato T, Arahata Y, Washimi Y, Nakamura A, Abe Y, et al. Cognitive- and motor-related regions in Parkinson’s disease: FDOPA and FDG PET studies. Neuroimage. 2004;22:553–561
  44. Ohara PT, Granato A, Moallem TM, Wang BR, Tillet Y, Jasmin L. Dopaminergic input to GABAergic neurons in the rostral agranular insular cortex of the rat. J Neurocytol. 2003;32:131–141
  45. Pani L, Porcella A, Gessa GL. The role of stress in the pathophysiology of the dopaminergic system. Mol Psychiatry. 2000;5:14–21
  46. Poewe W, Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease. Neurology. 2004;63(Suppl 3):S12–S16
  47. Rammsayer TH. Neuropharmacological evidence for different timing mechanisms in humans. Q J Exp Psychol. 1999;52:273–286
  48. Rinne JO. Nigral degeneration in Parkinson’s disease in relation to clinical features. Acta Neurol Scand Suppl. 1991;136:87–90
  49. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550–556
  50. Saade NE, Atweh SF, Bahuth NB, Jabbur SJ. Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain Res. 1997;751:1–12
  51. Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry. 2005;10:877–883
  52. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33
  53. Shyu BC, Kiritsy-Roy JA, Morrow TJ, Casey KL. Neurophysiological, pharmacological and behavioral evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia. Brain Res. 1992;572:216–223
  54. Singer C. Urinary dysfunction in Parkinson’s disease. Clin Neurosci. 1998;5:78–86
  55. Sorensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia: Are there different mechanisms in the processing of pain? (A double blind crossover comparison of analgesic drugs). J Rheumatol. 1997;24:1615–1621
  56. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia: Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol. 1995;24:360–365
  57. Sotres-Bayon F, Torres-Lopez E, Lopez-Avila A, del Angel R, Pellicer F. Lesion and electrical stimulation of the ventral tegmental area modify persistent nociceptive behavior in the rat. Brain Res. 2001;898:342–349
  58. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain. 2005;6:323–332
  59. Stiasny-Kolster K, Trenkwalder C, Fogel W, Greulich W, Hahne M, Lachenmayer L, et al. Restless legs syndrome: New insights into clinical characteristics, pathophysiology, and treatment options. J Neurol. 2004;251(Suppl 6):39–43
  60. Takeda R, Ikeda T, Tsuda F, Abe H, Hashiguchi H, Ishida Y, et al. Unilateral lesions of mesostriatal dopaminergic pathway alters the withdrawal response of the rat hindpaw to mechanical stimulation. Neurosci Res. 2005;52:31–36
  61. Talairach J, Tournoux P. Co-Planar Stereotactic Atlas Of The Human Brain. 1988;Stuttgart, Germany, Georg Thieme Verlag
  62. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia (Report of the Multicenter Criteria Committee). Arthritis Rheum. 1990;33:160–172
  63. Wood PB. Stress and dopamine: Implications for the pathophysiology of chronic widespread pain. Med Hypotheses. 2004;62:420–424
  64. Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant voxels in images of cerebral activation. Hum Brain Mapp. 1996;4:58–73
  65. Zweig RM. Sensory symptoms. In:  Factor SA,  Weiner WJ editor. Parkinson’s Disease: Diagnosis and Clinical Management. New York, NY: Demos Medical Publishing; 2002;p. 67–74

 Supported by Intramural Grant, Biomedical Research Foundation of Northwest Louisiana, and Faculty Development Grant, Department of Family Medicine, LSUHSC – Shreveport.

PII: S1526-5900(06)00843-1

doi: 10.1016/j.jpain.2006.05.014

The Journal of Pain
Volume 8, Issue 1 , Pages 51-58 , January 2007

Article Tools

* Image Usage & Resolution